As we advance in our understanding of the intricate interplay between insulin dysregulation and neddylation in cancer progression, careful evaluation of neddylation inhibitors in cancer patients with T2DM or hyperinsulinemia is necessary. This evidence concerns the gene INS and hyperinsulinism.